Gufic Biosciences (509079) investor relations material

Executive summary

• Indore plant is fully operational, with new depot and microsphere suites nearing completion and product tech transfers progressing as planned.

• Expansion into new geographies and hospital networks, including the incorporation of a new subsidiary in the Philippines with up to USD 250,000 investment and 99.99% ownership.

• Strategic shift in international business from distributor-led to IP-led, with new teams in key regions and direct market entry ambitions.

• Partnership with Hetero for GLP-1 (semaglutide) as a CMO, with revenue traction expected to increase in Q2 and Q3.

• Tie-up with Clinton Health Access Initiative for liposomal amphotericin B, targeting access to over 100 countries.

Financial highlights

• Q1 FY27 consolidated revenue rose to ₹26,081.80 lakhs from ₹22,691.15 lakhs in Q1 FY26; standalone revenue was ₹260.8 crore, up 15% year-over-year and 3% sequentially.

• EBITDA increased to ₹47.2 crore from ₹33.2 crore, with margin improving to 18.09% from 14.6% (year-over-year).

• Profit after tax grew to ₹22.46 crore from ₹12.1 crore, with PAT margin up to 8.61% from 5.3% (year-over-year).

• Basic and diluted EPS for Q1 FY27 stood at ₹2.22, up from ₹1.30 in Q1 FY26.

• Total comprehensive income for Q1 FY27 was ₹2,239.54 lakhs.

Outlook and guidance

• Medium-term growth expectations remain unchanged, targeting 15%-20% year-over-year revenue growth.

• Capacity utilization at Indore expected to reach 40%-45% by year-end, with further margin expansion anticipated post-EU certification.

• Operating leverage gains expected to start materializing by mid-FY28 as product mix shifts to higher-value offerings.

• Expansion into the Philippines is expected to facilitate business growth and international presence.

• Targeting 5–10% market share in identified geographies over 3–5 years.